In 2016, pembrolizumab was approved as a first-line therapy for NSCLC with PD-L1 expression of ≥50% in tumor tissues and for advanced NSCLC which has PD-L1 expression of ≥1% and has disease progression on or after platinum-containing chemotherapy [12]. The gene discussed is CD274; the disease is neoplasm.